Hematologic Malignancy
Mature B-Cell Non-Hodgkin Lymphoma
CI-CAN-00003259Explore in graph →
Hematologic792 active trials17 approved drugs43 evidence items
- NCIt
- C7056
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003259Explore in graph →
Clinical trials
2,506 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (393)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06313996 | A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma | withdrawn | Phase 3 | 0 | Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyINDUSTRY | 0 | Mar 18, 2026 | clinicaltrials |
| NCT05431179 | A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma | withdrawn | Phase 3 | 0 | Oncternal Therapeutics, IncINDUSTRY | 0 | Apr 21, 2023 |
| clinicaltrials |
| NCT04796922 | To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302) | withdrawn | Phase 3 | 0 | Incyte CorporationINDUSTRY | 0 | Jul 18, 2022 | clinicaltrials |
| NCT04849715 | A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma(CITADEL-310) | withdrawn | Phase 3 | 0 | Incyte CorporationINDUSTRY | 0 | Apr 29, 2022 | clinicaltrials |
| NCT02735876 | A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma | withdrawn | Phase 3 | 0 | Acerta Pharma BVINDUSTRY | 0 | May 13, 2016 | clinicaltrials |
| NCT02054559 | R-CHOP Alone vs. R-CHOP Plus Radiotherapy for Localized CD20+ DLBCL(ASPIRE) | withdrawn | Phase 3 | 0 | Asan Medical CenterOTHER | 1 | Feb 23, 2016 | clinicaltrials |
| NCT00319332 | A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen | withdrawn | Phase 3 | 0 | GlaxoSmithKlineINDUSTRY | 1 | Apr 17, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Mar 18, 2026source: clinicaltrials